Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
Acquisition hungry Neuraxpharm has struck another deal, this time to expand its business in Southeast Europe. The privately-owned central nervous system specialist has acquired Brain Therapeutics, an Athens-based, CNS-focused marketing and distribution company offering CNS products in its native Greece, as well as Cyprus and the Balkan countries.
“Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market, since the platform offers...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
